| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Regiafuran C (10-40 μM; 24 h) was not cytotoxic to human proximal tubule HK-2 cells, but it could dose-dependently reduce the expression of fibronectin, type I collagen, N-cadherin and vimentin in TGF-β1-stimulated human proximal tubule HK-2 cells [1]. Regiafuran C (10-40 μM; 24 h) could dose-dependently inhibit the activation of the TGF-β/Smad signaling pathway in TGF-β1-stimulated human proximal tubule HK-2 cells and reduce the levels of Wnt1, Wnt3a, GSK-3β, β-catenin, MMP7, MMP9, TGF-βRII, TGF-β1, p-Smad3, p-Smad2 and Smad4 [1]. Regiafuran C (40 μM; 24 h) significantly reduced the mRNA expression levels of fibronectin, type I collagen, N-cadherin, and vimentin in TGF-β1-induced human proximal tubule HK-2 cells [1]. Regiafuran C (40 μM; 24 h) reduced the protein levels of fibronectin, type I collagen, N-cadherin, and vimentin in TGF-β1-stimulated human proximal tubule HK-2 cells, as determined by immunofluorescence staining [1]. Regiafuran C (40 μM; 24 h) blocked the interaction between Smad3 and TGF-βRII in TGF-β1-stimulated human proximal tubule HK-2 cells [1].
|
|---|---|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: Human proximal tubule HK-2 cells, TGF-β1-stimulated human proximal tubule HK-2 cells Tested Concentrations: 10-40 μM Incubation Duration: 24 hours (co-incubated with TGF-β1) Experimental Results: At all test concentrations, cell viability was maintained at ≥90% of the control level. TGF-β1-induced upregulation of fibronectin, type I collagen, N-cadherin, and vimentin was downregulated in a dose-dependent manner. TGF-β1-induced upregulation of TGF-βRII, TGF-β1, p-Smad3, p-Smad2, and Smad4 was downregulated in a dose-dependent manner. The dose-dependent downregulation of TGF-β1-induced upregulation of Wnt1, Wnt3a, GSK-3β, β-catenin, MMP7, and MMP9 was observed. Real-time quantitative PCR[1] Cell Types: TGF-β1 stimulated human kidney proximal tubule HK-2 cells Tested Concentrations: 40 μM Incubation Duration: 24 hours (co-incubated with TGF-β1) Experimental Results: Significantly reduced the upregulation of fibronectin, type I collagen, N-cadherin and vimentin mRNA levels induced by TGF-β1. Immunofluorescence [1] Cell Types: TGF-β1 stimulated human renal proximal tubule HK-2 cells Tested Concentrations: 40 μM Incubation Duration: 24 hours (co-incubated with TGF-β1) Experimental Results: Reduced the fluorescence intensity increase induced by TGF-β1 stimulation of fibronectin, type I collagen, N-cadherin and vimentin. Reduced the fluorescence intensity increase induced by TGF-β1 stimulation of TGF-β1 and β-catenin. |
| References |
|
| Molecular Formula |
C25H28O5
|
|---|---|
| Molecular Weight |
408.49
|
| CAS # |
2059921-60-5
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
OC1=CC(C2=CC3=C(OC)C(C/C=C(CC/C=C(C)\C)\C)=C(O)C=C3O2)=CC(O)=C1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4480 mL | 12.2402 mL | 24.4804 mL | |
| 5 mM | 0.4896 mL | 2.4480 mL | 4.8961 mL | |
| 10 mM | 0.2448 mL | 1.2240 mL | 2.4480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
